Dupixent® (dupilumab) recommended for expanded eu approval by the chmp to treat children as young as six months old with severe atopic dermatitis

If approved, dupixent would be the first and only targeted medicine in the eu for these young children

REGN Ratings Summary

REGN Quant Ranking